Akebia Therapeutics, Inc.
NASDAQ:AKBABiotechnology
+$0.01 today
- Market cap
- $113.54M
- Beta
- 0.25
- P/E (TTM)
- -13.3
- EPS (TTM)
- -$0.08
Volume 7.09M
Average 4.03M
AKBA Depreciation & Amortization
Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.
Akebia Therapeutics, Inc.NASDAQ: AKBA
Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026
Depreciation & amortization growth accelerates
Q1 FY2026 depreciation & amortization of $328K rose 4.5% year over year, ahead of the -95.5% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 2.2% from the prior quarter. Over 3 fiscal years it compounded at -67.7% a year.
Context
- Depreciation & amortization amounted to 0.5% of revenue in FY2025, down 22.9 pp from a year earlier.
- Depreciation & amortization increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +4.5% holds above the trailing-twelve-month pace of -95.5%.
Sources:Income StatementText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the income statement
- Latest · FY2025
- 1.27M USD
- Year-over-year change
- -96.6%
- 4-year CAGR
- -57.2%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 1.27M | -96.6% |
| FY2024 | 2024-12-31 | 37.5M | -0.3% |
| FY2023 | 2023-12-31 | 37.63M | -0.2% |
| FY2022 | 2022-12-31 | 37.7M | -0.7% |
| FY2021 | 2021-12-31 | 37.97M | — |
Depreciation & Amortization vs competitors
How AKBA compares with its peers on the latest reported figures
- AKBA's LTM Mar 2026 depreciation & amortization of $1.28M is the 6th highest of the 10 companies compared; the peer median is $1.56M.
- Its year-over-year change of -95.5% is the lowest of 9, against a peer median of -0.3%.
- Depreciation & amortization amounts to 0.6% of revenue for AKBA, versus a peer median of 1.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $6.46M | +0.4% | +46.9% | 7.3% | |
| LTM Mar 2026 | $2.77M | -57.2% | +62.5% | 2.3% | |
| LTM Mar 2026 | $2.41M | -1.0% | +34.3% | 0.8% | |
| LTM Mar 2026 | $2.31M | +156.8% | +70.7% | 4.0% | |
| LTM Dec 2025 | $1.56M | — | — | 1.3% | |
| LTM Mar 2026 | $1.28M | -95.5% | -67.7% | 0.6% | |
| LTM Mar 2026 | $1.12M | -32.0% | -8.2% | — | |
| LTM Mar 2026 | $678K | -80.7% | -39.1% | 1.2% | |
| LTM Mar 2026 | $481K | +11.1% | +11.1% | — | |
| LTM Mar 2026 | $112K | +33.3% | -34.1% | — | |
| Peer median (excluding AKBA) | $1.56M | -0.3% | +22.7% | 1.8% | |
Competitors are the stored peer set for AKBA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 211.65M | 292.48M | 194.62M | 160.18M | 236.2M |
| Cost of Revenue | 81.49M | 22.5M | 74.15M | 63.18M | 39.46M |
| Gross Profit | 130.16M | 269.99M | 120.47M | 97M | 196.73M |
| Gross Margin | 61.5% | 92.3% | 61.9% | 60.6% | 83.3% |
| Research & Development | 147.85M | 165.99M | 63.08M | 37.65M | 62.36M |
| Selling, General & Admin | 174.14M | 138.6M | 100.23M | 106.55M | 107.48M |
| Operating Expenses | 394.66M | 350.77M | 166.73M | 147.48M | 173.24M |
| Depreciation & Amortization | 37.97M | 37.7M | 37.63M | 37.5M | 1.27M |
| EBITDA | (189.91M) | 3.06M | (8.27M) | (13.72M) | 21.73M |
| EBITDA Margin | -89.7% | 1.0% | -4.2% | -8.6% | 9.2% |
| Operating Income | (264.5M) | (80.78M) | (46.26M) | (50.47M) | 23.5M |
| Operating Margin | -125.0% | -27.6% | -23.8% | -31.5% | 9.9% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 19.94M | 15.69M | 6.03M | 18.19M | 24.18M |
| Other Income / Expenses | (17.52M) | (13.45M) | (5.67M) | (18.94M) | (27.22M) |
| Income Before Tax | (282.02M) | (94.23M) | (51.93M) | (69.41M) | (3.72M) |
| Pre-Tax Margin | -133.3% | -32.2% | -26.7% | -43.3% | -1.6% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 1.62M |
| Net Income | (282.02M) | (94.23M) | (51.93M) | (69.41M) | (5.35M) |
| Net Margin | -133.3% | -32.2% | -26.7% | -43.3% | -2.3% |
| EPS (Basic) | (1.48) | (0.58) | (0.28) | (0.33) | (0.02) |
| EPS (Diluted) | (1.48) | (0.58) | (0.28) | (0.33) | (0.02) |
| Weighted Avg Shares | 165.95M | 182.78M | 187.47M | 210.95M | 257.16M |
| Weighted Avg Shares (Diluted) | 165.95M | 182.78M | 187.47M | 210.95M | 257.16M |
Akebia Therapeutics, Inc.
NASDAQ:AKBA
Intrinsic Alpha fair value
Locked
Current Price
$0.41
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.